Table 2.
Cox regression univariate and multivariate survival analysis.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Variable | HR (95% CI) | P | HR (95% CI) | P |
| IMW | ||||
| No | 1 | 1 | ||
| Yes | 0.47 (0.28–0.78) | <0.01 | 0.43 (0.22–0.86) | 0.02 |
| Sex | ||||
| Male | 1 | |||
| Female | 1.09 (0.63–1.87) | 0.54 | ||
| ECOG | ||||
| 0 | 1 | 1 | ||
| 1 | 0.24 (0.12–0.49) | <0.01 | 0.20 (0.77–0.54) | <0.01 |
| 2 | 0.72 (0.36–1.46) | 0.37 | 0.53 (0.19–1.42) | 0.21 |
| 3 | 11.51 (3.94–33.57) | <0.01 | 8.56 (2.26–32.48) | <0.01 |
| WHO histopathology | ||||
| Grade 1–2 | 1 | |||
| Grade 3 | 0.79 (0.43–1.43) | 0.43 | ||
| Clinical stage | ||||
| Stage 3 | 1 | 1 | ||
| Stage 4 | 1.76 (0.93–3.33) | 0.07 | 1.59 (0.77–3.27) | 0.21 |
| Distant metastasis | ||||
| No | 1 | 1 | ||
| Yes | 1.5 (0.87–2.57) | 0.56 | 1.92 (1.03–3.56) | 0.04 |
| Comorbidity | ||||
| No | 1 | |||
| Yes | 1.27 (0.74–2.18) | 0.38 | ||
| Treatment approach | ||||
| Palliative therapy | 1 | 1 | ||
| Sequential CRT | 0.31 (0.11–0.73) | 0.04 | 0.24 (0.08–0.72) | 0.01 |
| Concurrent CRT | 0.17 (0.81–0.35) | <0.01 | 0.27 (0.06–1.09) | 0.07 |
| Chemotherapy only | 2.66 (0.55–12.97) | 0.22 | 7.32 (0.98–55.98) | 0.06 |
| Radiotherapy only | 0.09 (0.11–0.73) | 0.02 | 0.42 (0.01–0.62) | 0.02 |
CRT, chemoradiotherapy; ECOG, Eastern Cooperative Oncology Group; IMW, independent multidisciplinary work.